

3.7.5 Crisantaspase (Rylaze) Asparaginase

The [Crisantaspase \(Rylaze\) Asparaginase Module](#) is an educational tool for administration of Crisantaspase (Rylaze) Asparaginase. This is indicated for treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma patients who are intolerant of front line asparaginase therapy with pegaspargase (Oncaspar) or calaspargase pegol (Asparlas) due to allergic reactions or silent inactivation noted by Therapeutic Drug Monitoring (TDM).

This guidance document was developed by Dr. Paul Gibson, McMaster Children's Hospital, Pediatric Oncology Group of Ontario, in consultation with Virginia Cyr, CHEO, Kaniska Young Tai, The Hospital for Sick Children and Valerie Wade, Children's Hospital, London Health Sciences Centre.

Disclaimer: Source Accuracy

You are welcome to download and save a local copy of this document in the Word and/or PDF formats provided. As the POGO Satellite Manual is subject to ongoing revisions and updates by POGO, we recommend you regularly check the online version posted at <https://www.pogo.ca/satellite-manual/> to ensure you have the most up-to-date content. In the event of any inconsistency between the content of a local copy and the online version of the POGO Satellite Manual, the content of the online version shall be considered correct. Please see also the [POGO Satellite Manual Disclaimer](#).

Record of Updates

Version Number	Date of Effect	Summary of Revisions
2	05/08/2025	<ul style="list-style-type: none"> Original version posted.